About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range ...

Their pipeline is fully centered on Onvansertib, a small molecule aimed at inhibiting the polo-like kinase 1 (PLK1), for the treatment of RAS-mutated cancers, including metastatic colorectal ...

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

Detailed price information for Cardiff Oncology Inc (CRDF-Q) from The Globe and Mail including charting and trades.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management ...